HEART SENTRY - By lexingtonBioSciences.com

Lexington Bio Sciences new :Heart Sentry"!

Wednesday, August 29, 2018

Retire Fund Web Domain Package

Retire Fund Web Domain

On Sale!

You may also consider these RetireFund Domains on auction:


To buy any of these premium web addresses just click on the domain of your choice to see the details:



These two Domains were sold for these prices previously:

RETIRE.COM  $2,000,000
FUND.COM    $10,000,000

NOW!  Your company can own 6
Retire Fund Domains!!!

RetireFund - What are your clients doing?
                        "AFTER WORK"!

Note: The sale and Escrow will be handled by reliable third party broker Epik.com

Wednesday, July 25, 2018

Lexington Biosciences Receives HeartSentry USPTO Patent Approval!

VANCOUVER, BC – July 25, 2018) – Lexington Biosciences, Inc. (Toronto TSE: LNB) (OTCQB: LXGTF) is pleased to announce the issuance of U.S. Patent No. 10,028,664, which covers aspects of its HeartSentry device.

“Today’s news is a big deal for Lexington,” says Company CEO, Eric Willis. “The US Patent Office and our legal team did an extraordinary job in arriving at this approval so quickly. The fact that all key claims were reviewed and approved without significant amendment speaks volumes to the veracity of our research and the clearly defined parameters of the operating methodology. We also have numerous patents pending on individual aspects of the science, both domestically and overseas, but this particular patent approval should pave the way for subsequent approvals in other global jurisdictions.”

HeartSentry was designed by Lexington’s lead researcher, Chief
Scientific Advisor Jonathan S. Maltz, Ph.D., as a diagnostic device that provides a new approach to non-invasive measurement and monitoring of cardiovascular health. 

 The device assesses the function of a patient’s vascular endothelium, the vital innermost lining of the cardiovascular system. The Company designed HeartSentry to be highly portable, accurate, quick, and cost-effective, with the intent to position it to become the standard of care for cardiologists, general practitioners, and ultimately for patients as a first-line evaluation of cardiovascular health.

The public is invited to follow us on Facebook, Twitter and LinkedIn. To receive our newsletter and news alerts direct to your inbox, you can signup at any time on any of the signup opportunities or “contact” page of our website.

To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead.

About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of the cardiovascular system.  Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.

HeartSentry core technology was developed at the Lawrence Berkeley National Laboratory over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.  Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

On Behalf of the Board,
“Eric Willis”
Eric Willis
CEO  Director

Lexington Biosciences, Inc.
+1 (800) 320-2640

Thursday, June 21, 2018

Trade Wars never end well - History shows us why!

History's Not on the Market's Side in a Trade War - Article at Bloomberg


The first shots of a global trade war were fired on Friday as U.S. President Donald Trump announced a 25 percent levy on $50 billion of imports from China. The tariffs focus on “industrially significant technology,” and intend to hurt China for alleged theft of intellectual property rights. China responded within hours with a detailed list of imports from the U.S. valued at $50 billion that it would impose a similar 25 percent tax on...


Trumps Trade War makes no sense....

Washington Post

A Trade War with China damages both sides...

New York Times Article... 

Markets begin to take Trade War Seriously...

Wall Street Journal 

Trump's Trade War will hurt Economy....

Why Donald Trump's trade wars are so risky now... 


Wednesday, February 28, 2018

Lexington BoiSciences "Heart Sentry" Device may be the answer to pre-detection of heart disease!

Lexington Bio Sciences (LexingtonBioSciences.com)


Heart Disease and Heart Attacks are the number one killer of North Americans, and most people, worldwide. Nearly 1 in 3 deaths in the USA alone are attributed to Heart Attack and Stroke!

For 50% of these people, their "first" indication of a problem is a massive heart attack.  They have no warning whatsoever.

Though taking blood pressure and heart rates coupled with ultrasound techniques will sometimes indicate a problem, the fact remains that, only in 50% of all cases do these indicators work. Now, wouldn't it be great if there was a "Non-invasive" way of determining, with a lot more accuracy, if heart disease is prevalent in a patient, "before" the onset of a heart attack? Hey, wouldn't it be great if that test was no more bother than simply taking your blood pressure is?

Well, at this writing, there is such a device, currently in Clinical Trials, after 15 years of research and development in California Universities. Lexington BioSciences "HeartSentry" can measure something that has never been measured properly before. Endothelium

Endothelium, are the cells that line all arteries and are critical to the prevention of atherosclerosis, heart disease and stroke, the two leading causes of deaths worldwide (17.5 million people every year). 
The significant value of measuring endothelial function is supported by many peer-reviewed studies.

For ease of use this new, life saving technology has been incorporated into a simple blood pressure cuff.  Utilizing both blue tooth and cloud technology, the device to provide up-to-date, accurate readings of a patients complete cardiovascular health via electronic monitoring.

As you might expect, this is a significant development in a  multi-billion dollar market, and all the patents and the technology are owned by a MicroCap Business, owned and operated by PHD's - LexingtonBioSciences 

 More about HeartSentry.....

Disclosure: We own LNB Stock! 
Question: Do you? 

Behind Every Successful Company is an Elite Management Team

The principals, directors and advisers of Lexington Biosciences, Inc. (OTC: LXGTF) have been individually and collectively involved in raising extensive capital funding for their private and public companies. Team members have held numerous executive leadership positions encompassing biotechnology, and medical device companies, as well as multi-national corporations. The team includes inventors, scientists, and business people who have successfully started, built and grown multiple life science companies.

Eric Willis, Chief Executive Officer

Mr. Willis is an entrepreneurial healthcare technology executive with a track record of success in bringing products from initial concept to market. He is the past President and Chief Operating Officer of ParaPatch (2013–2015), where he was responsible for the development and launch of an over-the-counter women’s health product for the treatment of urinary incontinence. Prior to this, he served as President and CEO of InSite Medical Technologies (2008–2013) a venture backed start-up medical device company that developed a new method for performing epidural anesthesia. From 1994–2008 he served in a variety of executive and operational roles for cardiovascular medical device companies.

Doug Janzen, Chairman

Mr. Janzen has 20 years of experience in life sciences with leadership experience in corporate finance, business development, and operational management of life sciences companies. Mr. Janzen is currently Co-Founder and Managing Director of Northview Ventures. He serves as img alt Chairman and CEO of Aequus Pharmaceuticals (AQS-TSXV), a company that was founded within Northview. Prior to Northview Ventures, he was President and CEO of Cardiome Pharma (NASDAQ: CRME) During this time he raised over $300 million from investors, completed over $1 billion in licensing deals.

Greg Robertson, M.D., Medical Advisor

Dr. Greg Robertson is chief of the Emory Heart and Vascular Clinic at Johns Creek. At the Emory Johns Creek Hospital he is chief of cardiology and the medical director of the cardiac catheterization laboratory and interventional program. He is board certified in Vascular Medicine, Endovascular Medicine, Interventional Cardiology and Cardiovascular Medicine. He is an associate professor of medicine at Emory University. Dr. Robertson’s clinical expertise has focused on preventative care and using minimally-invasive vascular and cardiac treatment.

Rocco Rossi, Director

A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco Rossi is currently President and CEO of Prostate Cancer Canada. His unique blend of experience intersects general management, philanthropy, public policy, politics, business strategy, and new media. As CEO of the Heart and Stroke Foundation – one of Canada’s largest non-profit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over $500 million in total and launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of Toronto and for MPP.

We believe Opportunity is Knocking

It’s not everyday you are presented with the opportunity of investing in a company that’s within a $140-billion-dollar sector, with a real chance for FDA approval, the potential opportunity to sell their product within some of the largest big box retailers on the planet, the chance to capitalize off of a hot sector with public companies currently making triple digit gains in less than 2 years & not to mention you get to be a part of the beginnings of a company that’s primary goal is to SAVE LIVES!

Wednesday, November 1, 2017

DotCom (.Com) Domain Names are still the most sought after Web Domains Online Today

Web Domains, as you probably already know, are the Real-estate of the Internet. Domains are now essential to any business today, whether it is an international, national or local business.

The importance of a good Domain Name cannot be understated. In today's busy, online world, and in the real world, Business Marketing goes on and that Marketing "must" include a solid online address.

Because it was the first domain extension associated with business, the .Com has become synonymous with online business and Domains like Business.com, Yahoo.com, Google.com, Ebay.com, Sex.com, Porn.com, Apple.com, Twitter.com, Facebook.com etc etc have been valued in the tens of millions of dollars.

Thousands more have been bought and sold for millions or in the high six figures, and millions of .com Domains have been sold in the tens of thousands of dollars. To view this year's "year to date" sales chart/list visit: >> http://dnjournal.com/ytd-sales-charts.htm

If you have the time, For more of a historical research of domain sales, go to: http://dnjournal.com/archive/domainsales-archive.htm

We still have some Dot Com and Dot Net Domains for sale! Some of these were registered before the turn of the century.

They include:










Just click on the domain of your choice to see the asking price, or to make an offer!

Good luck with your business!